Nautilus Biotech

About:

Nautilus Biotech is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins.

Top Investors: Andera Partners, Auriga Partners, 123Venture, Rothschild & Co., Matignon Investissement & Gestion

Description:

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Total Funding Amount:

$20.8M

Headquarters Location:

Évry, Ile-de-France, France

Founded Date:

1999-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-04-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai